Welcome to our dedicated page for Pulsenmore SEC filings (Ticker: PLSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Pulsenmore's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Pulsenmore's regulatory disclosures and financial reporting.
Pulsenmore Ltd. reported full-year 2025 revenue of $12.5 million, up 374% from 2024, driven mainly by a $9.6 million one-time revenue from a settlement with GE Precision Healthcare that also canceled 15,000-unit orders and ended a component agreement. Excluding this, underlying revenues were far smaller.
The company’s net loss narrowed to $5 million from $10 million, as gross profit rose to $10.5 million and gross margin expanded to about 84% from 37%, despite higher operating expenses of $14.4 million tied to U.S. infrastructure, partnerships, and operations. Pulsenmore ended 2025 with $21.7 million in total liquid assets, including $7 million in cash and cash equivalents. Strategically, it secured FDA clearance for remote-use prenatal ultrasound in the U.S., obtained MDR CE certification in Europe for its early-screening product, and launched initial U.S. commercial programs integrating its home-use ultrasound into clinical workflows.
Pulsenmore Ltd., an Israeli medical device company, uses portable ultrasound technology for home and point-of-care imaging. Its main products are the Pulsenmore ES, cleared in markets including the United States, Europe and Israel, and the Pulsenmore FC, in early commercialization in Israel.
The company listed its ordinary shares on Nasdaq under “PLSM” in January 2026 and on the Tel Aviv Stock Exchange in June 2021. A one-for-eight reverse split of ordinary shares took effect on December 28, 2025. Financial statements are prepared under IFRS in New Israeli Shekels.
Pulsenmore remains loss‑making, reporting net losses of NIS 58.6 million in 2023, NIS 36.7 million in 2024 and NIS 15.9 million in 2025. Most revenue comes from Israel and is highly concentrated with Clalit Health Services. The company warns it may need additional capital, faces regulatory, competitive, cybersecurity and data‑privacy risks, and is exposed to political and economic instability in Israel and changing global trade and ESG requirements.
Pulsenmore Ltd. director and Chief Executive Officer Elazar Sonnenschein has filed an initial ownership report showing his holdings of the company’s ordinary shares. The filing lists 988,930 shares held directly.
It also reports 883,162 shares held indirectly through D.L.L.D. Consulting Ltd, a private company wholly owned by him.
Pulsenmore Ltd. VP R&D Sonnenschein Minelu filed an initial insider report showing existing stock option holdings. The filing lists options to purchase 6,093 Ordinary Shares at an exercise price of $6.4100 per share, expiring on February 1, 2033.
According to the notes, the options were granted on October 7, 2021 under the Pulsenmore Ltd. 2019 Amended Share Incentive Plan. They vest as 1,523 options on February 1, 2027, with the remaining options vesting in twelve equal quarterly installments from May 1, 2027 through February 1, 2030, subject to continued service. The exercise price was originally set in New Israeli Shekels and is shown here in U.S. dollars using a Bank of Israel exchange rate.
Pulsenmore Ltd. filed an initial ownership report for VP Software Development Shmouely Meir. He directly holds 13,812 Ordinary Shares and options over 6,093 Ordinary Shares with a $6.41 exercise price, vesting from February 1, 2027 through February 1, 2030 under the 2019 share incentive plan.
Pulsenmore Ltd. director Racheli Guz-Lavi filed an initial Form 3 reporting derivative holdings rather than a new trade. She holds options to purchase Ordinary Shares at an exercise price of 0.032 per share, with tranches first exercisable in 2022 and 2023 and expiring on January 5, 2028. Footnotes state these options were granted on January 5, 2021, are fully vested and exercisable, and are held through a trustee to qualify for Israeli tax benefits under Section 102.
Pulsenmore Ltd. Chief Financial Officer Eran Hirsh filed an initial ownership report showing options to purchase 7,312 Ordinary Shares. These options have an exercise price of $6.41 per share and expire on February 1, 2033. They were granted on August 14, 2024 and vest from February 1, 2027 through February 1, 2030, subject to continued service.
Pulsenmore Ltd. director Jonathan Adereth has filed an initial Form 3 reporting his ownership in the company. The filing shows that he directly holds 129,062 Ordinary Shares following the reported position. This is an ownership snapshot rather than a new share purchase or sale.
A footnote explains that, under Section 102 of the Israeli Tax Ordinance, securities issued to employees or directors in connection with the Pulsenmore Ltd. 2019 Amended Share Incentive Plan must be registered in the name of a trustee to qualify for certain tax benefits.
Pulsenmore Ltd. filed an initial ownership report for its GC & Corporate Secretary, Michael Hamelsdorf, showing a derivative position in company equity. He holds options to purchase 6,093 Ordinary Shares at an exercise price of $6.4100 per share, expiring on February 1, 2033.
The options were granted on October 19, 2023 and will vest over time. According to the vesting schedule, 1,523 options vest on February 1, 2027, with the remaining options vesting in twelve equal quarterly installments from May 1, 2027 through February 1, 2030, subject to his continued service.
Pulsenmore Ltd. director Anat Loewenstein filed an initial ownership report showing holdings of options to purchase ordinary shares. The options carry an exercise price of $44.0400 per share and are scheduled to expire on August 10, 2028.
The options were granted on August 10, 2021. According to the filing, 20,508 options are already fully vested and exercisable, while 1,464 additional options vest on May 10, 2026 and 1,465 on August 10, 2026. To qualify for certain Israeli tax benefits, these securities must be registered in a trustee’s name under Pulsenmore’s 2019 Amended Share Incentive Plan.